New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.

Expiry of Novo Nordisk’s UK patent for Saxenda seen as offering a ‘dry run’ for future generic versions of Ozempic ...

Pfizer was riding high during the pandemic but has been overtaken by rivals including Eli Lilly and Novo Nordisk whose weight ...

Novo Nordisk, whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...

A pharmacist warns that off-brand Ozempic, Zepbound, and other weight loss products carry undisclosed risks for consumers.

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

Eli Lilly and Company (NYSE:LLY) stands out as one of the best growth stocks in the healthcare sector owing to the vast sales ...

If Medicare were to start covering popular weight loss drugs such as Wegovy and Zepbound, it could increase federal spending ...

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its ...

The FDA has decided to reconsider its previous decision that barred drug compounders from selling their versions of Eli Lilly ...